Digestive system neuroendocrine tumor, grade 1/2

This study tests whether a second round of targeted radiation therapy (177Lu-DOTATATE) works better than standard drugs (everolimus, sunitinib, or cabozantinib) for people with advanced neuroendocrine tumors of the digestive system that have spread and cannot be removed by surger…

This study compares two schedules of the radioactive drug Lu177-Dotatate in 166 people with slow-growing midgut neuroendocrine tumors. One group gets the drug every 8 weeks (standard), the other every 16 weeks. The goal is to see if the less frequent schedule causes fewer blood-r…

This early-stage trial is testing a new drug called BL-M14D1 in about 120 people with advanced small cell lung cancer or other neuroendocrine cancers that have spread or cannot be removed. The drug works by homing in on a protein called DLL3 found on these cancer cells and delive…

This early-phase trial tests a new radioactive drug called RYZ401 in people with neuroendocrine tumors and other solid tumors that have a specific protein on their surface. The drug delivers a powerful radioactive particle directly to cancer cells. The study aims to find the safe…

This study tests whether adding a radioactive drug (177Lu-DOTA-TATE) to standard therapy (octreotide) helps control advanced neuroendocrine tumors of the gut or pancreas better than standard therapy alone. About 240 newly diagnosed patients with slow-growing but high-burden tumor…

This study tests whether combining Lutathera (a radioactive drug given by IV) with Olaparib (a pill) can shrink neuroendocrine tumors in the pancreas or intestine that cannot be removed by surgery. About 56 adults will receive the treatment over several cycles. The goal is to fin…

This early-stage trial tests a radioactive drug that seeks out and delivers radiation directly to cancer cells with a specific protein (somatostatin receptor). It is for adults with advanced lung, kidney, head and neck, digestive tract, or adrenal gland tumors that cannot be remo…

This study tests a new radioactive drug, [212Pb]VMT-alpha-NET, in people with advanced gastrointestinal neuroendocrine tumors or pheochromocytoma/paragangliomas that have already been treated with radiation therapy. The drug is designed to attach to a protein on the surface of th…

This study tests whether removing as much tumor as possible through surgery before giving a targeted radioactive drug (Lutetium Lu 177 dotatate) works better for people with slow-growing neuroendocrine tumors that have spread to the liver. Six adults with grade 1 or 2 tumors will…

This study tests whether a radioactive drug called lutetium-177 oxodotreotide, when combined with a standard dose of octreotide, works better than a high dose of octreotide alone for people with advanced neuroendocrine tumors of the gut or pancreas. About 220 adults aged 18-75 wi…

This study tests a new drug called [212Pb]VMT-α-NET, which delivers a powerful type of radiation (alpha particles) directly to tumor cells that have a specific marker (SSTR2). The trial includes 300 adults with advanced neuroendocrine tumors or meningioma that cannot be removed b…

This study tests whether adding a targeted drug (sirolimus) to a standard hormone-blocking injection (octreotide) can better control advanced neuroendocrine tumors of the stomach, intestines, or pancreas. About 298 adults with tumors that cannot be removed by surgery will receive…

This study tests a combination of two drugs—cabozantinib (a daily pill) and lanreotide (a monthly injection)—in people with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have stopped responding to prior treatments. The trial has two phases: the first finds…

This study tests a new drug called RYZ101 in people with advanced neuroendocrine tumors (GEP-NETs) that have grown after prior radiation therapy. The trial has two parts: first finding the right dose, then comparing RYZ101 to standard treatments like everolimus or sunitinib. Abou…

This study is tracking 50 adults with neuroendocrine tumors who are receiving peptide receptor radionuclide therapy (PRRT). Researchers are collecting data on patient characteristics, treatment responses, survival, and side effects. The goal is to better understand who benefits f…

This early-phase study tests whether adding focused external radiation (SBRT) before a standard radioactive drug therapy (177Lu-DOTATATE) is safe and effective for people with large, inoperable neuroendocrine tumors of the digestive system. About 15 adults whose tumors have grown…

This phase 2 trial is testing a new radioactive drug called Terbium-161 DOTATATE in 20 people with advanced neuroendocrine tumors that have spread and stopped responding to standard treatment. The drug delivers radiation directly to cancer cells, aiming to control the disease wit…

This Phase 3 trial tests whether adding chemotherapy (capecitabine and temozolomide) to standard radiation therapy (PRRT) helps people with advanced neuroendocrine tumors of the stomach, pancreas, or intestines that show high activity on FDG PET scans. The study plans to enroll 1…

This pilot study is testing a new radioactive tracer called 89Zr-TLX250, which targets a protein (CAIX) found on certain tumor cells. The goal is to see if PET-CT scans using this tracer can detect more tumor lesions in people with liver cancer, bile duct cancer, or neuroendocrin…

This study tests a new radioactive imaging agent called 68Ga-HA-DOTATATE to see if it can safely and accurately detect neuroendocrine tumors using PET/CT scans. About 600 people with known or suspected tumors will receive the agent and be followed for one year. The goal is to imp…

This study tests whether a new type of PET scan that uses two different tracers at the same time can find and stage liver cancer and pancreatic neuroendocrine tumors better than standard single-tracer scans. Researchers will compare the number and location of tumors seen with the…

This study enrolls people with endocrine tumors (such as thyroid, parathyroid, adrenal, or pancreatic tumors) who are scheduled for surgery or biopsy. Researchers collect samples of the tumor, nearby healthy tissue, blood, and urine to analyze genetic and molecular changes. The g…

This study is for Black adults newly diagnosed with gastrointestinal cancer. It focuses on ensuring patients receive proper biomarker testing and evidence-based care, helping them find and join clinical trials if they choose, and providing easy-to-understand information about the…

This study looks at whether adding a geriatrician (a doctor who specializes in care for older adults) to cancer treatment can improve outcomes for people aged 70 and older with gastrointestinal cancers like stomach, colon, or pancreatic cancer. Researchers will test if an online …

This study looks at whether measuring the amount of certain targeted cancer drugs in the blood can help find the best dose for each patient. It involves adults with advanced digestive cancers like colorectal, liver, and stomach tumors who are already taking these medications. By …

This study will analyze medical records of over 4,000 people newly diagnosed with gastroenteropancreatic neuroendocrine tumors (GEP-NET) in the U.S. Researchers aim to understand which treatments are used, in what order, and how long patients stay on them. The goal is to describe…

This study looks at how factors like age, sex, tumor grade, and location influence how well treatments work for people with well-differentiated gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Researchers will follow 450 patients to see how long their disease stays und…

This study is testing whether a special type of ultrasound (called D-CEUS) can predict if a targeted radiation therapy (PRRT) is working in people with advanced neuroendocrine tumors of the pancreas or gut. About 30 adults with these tumors will get D-CEUS scans before, during, a…

This study at Strasbourg University Hospital will check the nutritional status of 100 adults with gastroenteropancreatic neuroendocrine tumors. Researchers want to see if malnutrition is linked to worse outcomes. The goal is to understand whether improving nutrition could help pa…

This study is looking at people with a rare type of digestive system cancer called GEP-NET who are receiving a targeted radiation therapy (PRRT). Researchers will use special PET-MRI scans and artificial intelligence to find patterns that predict how well the treatment works. The…